Published Date: 11/06/2023
Expiration Date: 09/12/2026
On a recent survey, approximately one-third of our audience responded that they have patients with multi-drug resistant (MDR) HIV-1, which was higher than we anticipated. Although we hope the absolute number of patients failing therapy is small, this statistic underscores the reality that a significant number of us need to continue searching for new treatment options/classes/strategies that can serve the needs of our most vulnerable patients. PRN continues to spotlight emerging treatment research, and we are pleased to continue this effort with Dr. Ali Rai, from the National Institute of Allergy and Infectious Diseases (NIAID), who will help us understand the dimensions of the current challenge, utilize the most up-to-date methods for determining HIV resistance, and ways that you can help your patients access research studies for novel treatment modalities.
Dr. Rai earned a Bachelor of Medicine, Bachelor of Surgery (M.B.,B.S.) from Aga Khan University Medical College in Karachi where he helped to identify and shed light on the HIV situation in Pakistan. After completing medical school, he joined Prof. Andrew McMichael and Prof. Sarah Rowland-Jones at the Weatherall Institute of Molecular Medicine at Oxford as a Rhodes Scholar to study immune corelates of protection in a cohort of long-term non-progressors analyzing HLA, T-cell, ADCC and ADCVI responses. After completing his D.Phil. in Clinical Medicine, he became a part of the Physician Scientist Training Program at the University of Cincinnati where he completed his residency in Internal Medicine, followed by a fellowship in Infectious Diseases. He was faculty at the University of Cincinnati prior to moving over to NIAID, NIH in 2021. Dr Rai’s research focus is on HIV Multi-Drug resistance, and he is currently the Principal Investigator for Protocol 22-1-0008: A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 Infection.